Acumen Pharmaceuticals Reports First Patient Dosing with Sabirnetug in P-II (ALTITUDE-AD) Study for Early Alzheimer’s Disease
Shots:
- The P-II (ALTITUDE-AD) study assesses the safety & efficacy of sabirnetug (35mg/kg or 50mg/kg, Q4W) vs PBO to treat early AD patients (n=~540) in the US & Canada, to be expanded in EU & UK. The dosing was based on P-I (INTERCEPT-AD) study results. A P-I bioavailability study for SC formulation is expected in mid-2024
- The P-I (INTERCEPT-AD) study in 62 individuals showed reduced amyloid plaque with sabirnetug vs approved therapies, low rates of ARIA-E & evidence of target engagement, confirming proof of mechanism
- Sabirnetug, the first humanized mAb, has the ability of selective target engagement of AβOs that is a toxic form of Aβ which gets accumulated early in AD leading to synaptic dysfunction & neurodegeneration
Ref: Acumen Pharmaceuticals | Image: Acumen Pharmaceuticals
Related News:- Acumen Pharmaceuticals Presents P-I Trial (INTERCEPT-AD) Results of ACU193 for Early Alzheimer’s Disease at AAIC 2023
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
